Back to top

Image: Bigstock

Is a Surprise Coming for HOOKIPA (HOOK) This Earnings Season?

Read MoreHide Full Article

Investors are always looking for stocks that are poised to beat at earnings season and HOOKIPA Pharma Inc. (HOOK - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because HOOKIPA is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for HOOK in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 50 cents per share for HOOK, compared to a broader Zacks Consensus Estimate of a loss of 53 cents per share. This suggests that analysts have very recently bumped up their estimates for HOOK, giving the stock a Zacks Earnings ESP of +4.76% heading into earnings season.

HOOKIPA Pharma Inc. Price and EPS Surprise

HOOKIPA Pharma Inc. Price and EPS Surprise

HOOKIPA Pharma Inc. price-eps-surprise | HOOKIPA Pharma Inc. Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that HOOK has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for HOOKIPA, and that a beat might be in the cards for the upcoming report.

Zacks Top 10 Stocks for 2021

In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?

Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2021 today >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


HOOKIPA Pharma Inc. (HOOK) - free report >>

Published in